Primary myelofibrosis

9 trials MedDRA PT
9 Registered trials
0 Recruiting
7 Unique sponsors
13 Unique IMPs
8 Commercial trials
Drug classes (ATC)
G Urology/Gynaecology (ATC G) 1
H Endocrinology (ATC H) 1
L Oncology (ATC L) 3
B Haematology (ATC B) 3
— ATC code not specified 3
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Kinase inhibitor 3 substances
IMiD 1 substance
Interferon 1 substance
Corticosteroid 1 substance
Receptor fusion protein 1 substance
Supportive / diluent 1 substance
Phase III: 4 Phase II/III: 1 Phase II: 2 Phase I/II: 2

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

4 trials
  • Celgene Corp. Commercial
    LUSPATERCEPT
    2022-502498-40-00 8 countries 2019 n=139 Orphan
    Ended
  • Celgene Corp. Commercial
    LUSPATERCEPT; SODIUM CHLORIDE
    2023-507890-17-00 12 countries 2021 n=150 Orphan
    Ended
  • Novartis Pharma AG Commercial
    PELABRESIB MONOHYDRATE; RUXOLITINIB
    2025-523555-66-00 9 countries n=173
    Pending
  • Sobi Inc. Commercial
    PACRITINIB
    2024-515953-52-00 8 countries 2020 n=207
    Ended

Phase II/III

1 trial
  • Kartos Therapeutics Inc. Commercial
    DANAZOL; HYDROXYCARBAMIDE; LENALIDOMIDE; NAVTEMADLIN; PEGINTERFERON ALFA-2A; PREDNISONE
    2024-513912-89-00 13 countries 2018 n=253
    Ended

Phase II

2 trials
  • Glaxosmithkline Research & Development Limited Commercial
    LUSPATERCEPT; MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
    2024-518225-15-00 4 countries n=51 Orphan
    Pending
  • Karyopharm Therapeutics Inc. Commercial
    IMP not specified
    2024-513605-31-00 2 countries 2021 n=28
    Ended

Phase I/II

2 trials
  • Kartos Therapeutics Inc. Commercial
    NAVTEMADLIN
    2024-514468-26-00 2 countries 2020 n=26
    Ended
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    TASQUINIMOD
    2024-511565-11-00 2 countries 2025 n=26
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Kartos Therapeutics Inc. Commercial 2 Phase II/III, Phase I/II 0
Celgene Corp. Commercial 2 Phase III 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase II 0
Karyopharm Therapeutics Inc. Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase III 0
Sobi Inc. Commercial 1 Phase III 0
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic 1 Phase I/II 0
New trials by year
2019
1
2020
2
2021
2
2025
1
← All indication landscapes